Pharmaceutical giant Johnson & Johnson has agreed to buy fellow New Jersey-based company Intra-Cellular Therapies in a deal worth $14.6 billion, marking another large player’s entry into the neuroscience market. The acquisition includes Intra-Cellular’s approved schizophrenia treatment Caplyta and potentially lucrative antidepressant combination therapy for major depressive disorder. Johnson & Johnson will pay $132 per share in cash, a 60% premium on Intra-Cellular’s closing price Friday.
Source: https://www.statnews.com/2025/01/13/jnj-intracellular-caplyta-mental-health-neuroscience-acquisition